Our Solutions

e bulletin


  • E-Bulletin

    January 2019

    Jan 7, 2019

    2018 was a year of challenge, achievement, growth, and excellence at Altasciences.

  • E-Bulletin

    November 2018

    Nov 19, 2018

    Tackling metabolic disorders - a Glucagon case study, our latest assay list, and more

  • E-Bulletin

    October 2018

    Oct 17, 2018

    The Impact of Biosimilars on Drug Development and Key Study Considerations

  • E-Bulletin

    Customized Biostatistics Services

    Aug 22, 2018

    No matter the scale and scope of your study, whether it's local or international, Altasciences offers customized biostatistics services that suit your needs.

  • E-Bulletin

    Drug-Drug Interaction Studies

    Aug 10, 2018

    Do you have a Drug-Drug Interaction study in your pipeline? See the unique advantages Altasciences offers to complete quality DDI studies on time and cost-effectively.

  • E-Bulletin

    July 2018

    Jul 23, 2018

    Steps the FDA has taken to limit the misuse and abuse of prescription drugs, our tips on how to conduct a Human Abuse Potential (HAP) study, and a recent HAP case study.

  • E-Bulletin

    May 2018

    May 22, 2018

    FAQs on Clinical Studies Involving Oligonucleotides

This site uses cookies to store information on your computer and improve your browsing experience. By remaining on this site, you consent to the placement of these cookies. Read our Cookie Policy to learn more.